Study guide
16.2 National Tuberculosis Elimination Programme & NVBDCP
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
16.2 National Tuberculosis Elimination Programme & NVBDCP
Key Takeaways Explain This Topic AI
The National Tuberculosis Elimination Programme (NTEP) targets TB elimination in India by 2025 using the Detect-Treat-Prevent-Build (DTPB) strategy and upfront NAAT testing (CBNAAT/Truenat) for universal drug susceptibility screening.
Standard daily Fixed-Dose Combination (FDC) regimen for drug-susceptible pulmonary TB consists of a 2-month Intensive Phase of HRZE (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol) followed by a 4-month Continuation Phase of HRE.
Nikshay Poshan Yojana provides direct benefit transfer (DBT) of ₹500 per month to all registered TB patients throughout the duration of anti-tubercular treatment to support nutritional requirements.
National Vector Borne Disease Control Programme (NVBDCP) integrates control of 6 major vector-borne diseases: Malaria, Dengue, Chikungunya, Japanese Encephalitis, Kala-azar, and Lymphatic Filariasis.
Triple Drug Therapy (IDA: Ivermectin + DEC + Albendazole) is the WHO-recommended Mass Drug Administration (MDA) strategy for accelerating Lymphatic Filariasis elimination in endemic Indian districts.
Last updated: July 2026
National Tuberculosis Elimination Programme & NVBDCP
National health programs form a substantial portion of the UPSC Combined Medical Services (CMS) Community Medicine paper. Programmatic targets, diagnostic algorithms, therapeutic regimens, and operational guidelines under the National Tuberculosis Elimination Programme (NTEP) and National Vector Borne Disease Control Programme (NVBDCP) are examined extensively.
1. National Tuberculosis Elimination Programme (NTEP)
In 2020, India renamed the RNTCP to the National Tuberculosis Elimination Programme (NTEP) , signaling a strategic shift from tuberculosis control to elimination by 2025 (5 years ahead of the Sustainable Development Goal [SDG] global target of 2030).
Strategic Pillars: The DTPB Framework
Detect: Find all cases (active and passive case finding) with upfront rapid molecular diagnostics.
Treat: Initiate 100% of notified TB patients on appropriate, daily fixed-dose combination (FDC) anti-TB regimens with digital adherence monitoring.
Prevent: Scale up Tuberculosis Preventive Treatment (TPT) among contacts, airborne infection control, and BCG vaccination.
Build: Strengthen health systems, multi-sectoral partnerships, civil society engagement, and political commitment.
NTEP Upfront Diagnostic Pathway
NTEP has phased out sputum smear microscopy as the primary diagnostic tool in favor of upfront rapid molecular testing (NAAT) for all presumptive TB cases:
CBNAAT (Cartridge-Based Nucleic Acid Amplification Test / GeneXpert): Automated real-time PCR assay that simultaneously detects M. tuberculosis complex DNA and mutations conferring Rifampicin resistance (rpoB gene) within 2 hours .
Truenat: Microchip-based real-time PCR developed in India; portable, battery-operated, suitable for peripheral PHCs.
Universal Drug Susceptibility Testing (Universal DST): Every diagnosed TB patient undergoes DST for Rifampicin upfront. If Rifampicin resistance is detected, specimens undergo Line Probe Assay (LPA) or Liquid Culture DST (MGIT 960) for second-line drugs (Fluoroquinolones, Bedaquiline, Linezolid).
NTEP Treatment Regimens for Drug-Susceptible TB (DS-TB)
NTEP utilizes daily Fixed-Dose Combinations (FDCs) packaged in blister packs based on weight bands, administered under direct observation / digital support:
Phase Duration Drugs Included (Daily FDC) Blister Pack Color Code
Intensive Phase (IP) 2 Months 4 Drugs: Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E) [ 2HRZE ] Red Strip
Continuation Phase (CP) 4 Months 3 Drugs: Isoniazid (H), Rifampicin (R), Ethambutol (E) [ 4HRE ] Yellow Strip
Note: Pyrazinamide is stopped during CP. If a patient remains sputum-positive at the end of IP (2 months), CP is started without extension, and sputum is sent for NAAT / Line Probe Assay to rule out drug resistance.
Drug-Resistant TB (DR-TB) Definitions & Regimens
Rifampicin Resistant TB (RR-TB): Resistance to Rifampicin detected by NAAT or liquid culture, with or without resistance to other drugs.
Multidrug Resistant TB (MDR-TB): Resistance to at least Isoniazid (H) and Rifampicin (R) .
Extensively Drug-Resistant TB (XDR-TB): MDR-TB plus resistance to any Fluoroquinolone (Levofloxacin or Moxifloxacin) AND at least one Group A drug (Bedaquiline or Linezolid).
BPaLM Regimen: Modern 6-month fully oral regimen for MDR/RR-TB comprising Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin .
Patient Support & Digital Platforms
Nikshay Portal: Web-based notification and patient management database. Mandatory for both public and private health facilities.
Nikshay Poshan Yojana: Direct Benefit Transfer (DBT) scheme providing ₹500 per month to all registered TB patients throughout anti-TB treatment duration for nutritional support.
Tuberculosis Preventive Treatment (TPT): Recommended for all household contact children <5 years, HIV-infected individuals, and household contacts ≥5 years with positive TST/IGRA after ruling out active TB. Regimen: Isoniazid daily for 6 months (6H) or Isoniazid + Rifapentine weekly for 12 weeks (3HP) .
2. National Vector Borne Disease Control Programme (NVBDCP)
NVBDCP is an umbrella program for the prevention and control of 6 major vector-borne diseases in India:
- Malaria
- Dengue
- Chikungunya
- Japanese Encephalitis (JE)
- Kala-azar (Visceral Leishmaniasis)
- Lymphatic Filariasis
- A. Malaria Elimination Strategy (NFME 2016–2030)
India aims for zero indigenous malaria cases by 2030 . Districts are stratified based on API:
Category 0 (Prevention of Re-introduction): 0 cases.
Category 1 (Elimination Phase): API < 1 per 1,000 population.
Category 2 (Pre-elimination Phase): API 1 to 2 per 1,000 population.
Category 3 (Intensified Control Phase): API ≥ 2 per 1,000 population.
Anti-Vector Measures under NVBDCP
Indoor Residual Spraying (IRS): Applied to indoor wall surfaces where mosquitoes rest. Carried out in high-risk areas (API ≥ 2). Insecticides used: Synthetic Pyrethroids (Alphacypermethrin, Deltamethrin), Malathion (5%), or DDT (50% WP). Minimum 2 rounds required during transmission season, achieving >85% room coverage .
Long-Lasting Insecticidal Nets (LLINs): Impregnated with pyrethroids (e.g., Deltamethrin, Permethrin) bound to synthetic fibers. Effective for 3 years or 20 washes without re-treatment. Distributed free of charge in areas with API ≥ 1.
Biological Control: Introduction of larvicidal fish— Gambusia affinis (top feeding minnow) and Poecilia reticulata (guppy)—into slow-flowing streams, wells, and large water bodies. Chemical larviciding uses Temephos (Abate) or Bacillus thuringiensis israelensis (Bti).
B. Kala-azar (Visceral Leishmaniasis) Elimination Programme
Agent: Leishmania donovani (protozoan parasite).
Vector: Phlebotomus argentipes (Sandfly). Breeds in moist, organic-rich soil, cracks in mud walls, and cattle sheds. Extremely small size (1.5–3.5 mm).
Endemic Focus: Bihar, Jharkhand, West Bengal, and Eastern Uttar Pradesh.
Elimination Target: <1 case per 10,000 population at the Block level .
Diagnostic Tool: rK39 Immunochromatographic Rapid Diagnostic Test (detects antibodies against 39-amino-acid recombinant leishmanial antigen).
First-Line Treatment: Single intravenous infusion of Liposomal Amphotericin B (10 mg/kg) .
Vector Control: 2 rounds of Indoor Residual Spraying (IRS) with Synthetic Pyrethroids (Deltamethrin) up to a height of 6 feet on indoor wall surfaces.
C. Lymphatic Filariasis Elimination Programme
Agent in India: Wuchereria bancrofti (99% of Indian cases) and Brugia malayi (1%, localized to coastal Kerala/Odisha).
Vector: Culex quinquefasciatus (breeds in dirty, polluted, stagnant water, sewage, and cesspools).
Elimination Target: Microfilaria (Mf) rate < 1% in endemic districts.
Mass Drug Administration (MDA) Strategy:
Triple Drug Therapy (IDA Regimen): Administered once annually in target endemic districts to all individuals aged ≥2 years (excluding pregnant women and critically ill):
Ivermectin: 200 µg/kg body weight (height-based dosing chart).
Diethylcarbamazine (DEC): 6 mg/kg body weight.
Albendazole: 400 mg fixed single dose.
Morbidity Management & Disability Prevention (MMDP): Foot hygiene, anti-fungal cream, and limb elevation for Lymphedema; hydrocelectomy for Hydrocele cases.
D. Japanese Encephalitis (JE) Control Strategy
Agent: Flavivirus.
Vector: Culex tritaeniorhynchus and Culex vishnui group. Breeds extensively in paddy fields and flooded vegetated water bodies.
Amplifier Host: Pigs and wild water birds (herons, egrets). Humans are dead-end hosts .
Vaccination: SA-14-14-2 (live attenuated cell-culture derived vaccine) under the Universal Immunization Programme. 2 doses: Dose 1 at 9 completed months (along with MR-1) and Dose 2 at 16–24 months.